Trial Profile
Research on the efficacy of LOTRIGA on coronary plaque formation and inflammatory cytokine in patients undergoing percutaneous coronary intervention
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2013
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; HMG-CoA reductase inhibitors
- Indications Atherosclerosis
- Focus Therapeutic Use
- 09 Aug 2013 New trial record